TAT-NR2B9C is a synthetic peptide fusion of the nine C-terminal residues of the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor and the cell membrane protein transduction domain of the HIV-1 tat protein. It is a postsynaptic density protein-95 (PSD95) inhibitor with neuroprotective properties. It is under development for the treatment of acute stroke and acute cerebral ischemia.

Tertomotide (also known as GV1001) is a synthetic telomerase-specific peptide vaccine patented by Norsk Hydro Asa for the cancer treatment. The agent was initially developed as a cancer vaccine, for example, against pancreatic and prostate cancer. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with Tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte response against telomerase-expressing cells. Subsequently, in vivo studies have demonstrated the efficacy of Tertomotide in alleviating benign prostatic hyperplasia (BPH) symptoms by reducing the size of the prostate gland. The mechanism of action of Tertomotide has been proposed to be through its dual activity as a GnRH inhibitor and 5a-reductase inhibitor. The GnRH antagonist activity has been established by co-immunoprecipitation assay, demonstrating an interaction between Tertomotide and the GnRH receptor, which was abolished by pre-treatment with anti-GnRH receptor antibody.

AC-2592 (glucagon-like peptide 1, or GLP-1) was being in development by Amylin Pharmaceuticals for the treatment of severe congestive heart failure. AC-2592 is a glucagon like peptide 1 receptor agonist.

Forigerimod (also known as IPP-201101) a phosphopeptide is being investigated for the treatment of Lupus Erythematosus, Systemic. This drug is completed phase III clinical trials and is ready for licensing.